Business
CFO appointment
CFO appointment.
About this update from Inspiration Healthcare Group Plc
[{"type":"text","content":"\n\nInspiration Healthcare Group plc\n(\"Inspiration Healthcare\", the \"Company\" or the \"Group\")\n \nAppointment of Chief Financial Officer\nand\nGrant of Options\n \nInspiration Healthcare Group plc (AIM: IHC), the global medical technology company pioneering best-in class, specialist neonatal intensive care medical devices, announces the appointment of Alan Olby ACA as Chief Financial Officer and a Director of the Company, effective immediately.\n \nAlan is an experienced and commercially focused healthcare CFO, with extensive international and operational experience within fast-growing listed and private healthcare companies. He spent 16 years at Sinclair Pharma, of which 12 years were as CFO and a member of the executive leadership team and he was instrumental in transforming the company into a fast growth global aesthetics business, which was sold to Huadong Medicine Co Ltd for £165 million in 2018.\n \nDuring his tenure he oversaw several successful capital raises, and a number of strategic M&A transactions, including the disposal of the non-core business to Alliance Pharma for £132 million in 2015. Prior to Sinclair Pharma, Alan was Group Financial Controller of Xenova Group plc and KS Biomedix plc.\n \nNeil Campbell, Chief Executive Officer of Inspiration Healthcare said: \"We are delighted to have someone of Alan's calibre join Inspiration Healthcare. His track record of building and growing a commercial healthcare business and his experience of capital markets will be invaluable as we continue to execute our strategy and build a world leading innovative medical technology company focused on neonatal intensive care.\"\n \nAlan Olby, incoming Chief Financial Officer commented: \"I am delighted to be joining Inspiration Healthcare at this exciting stage in the Group's development. The Group's world class design and manufacturing expertise enables it to provide a broad range of specialist, innovative products that address the critical needs within the global neonatal market and I look forward to working to accelerate the Group's growth strategy.\"\n \nIn accordance with Schedule 2 (g) of the AIM Rules for Companies, Alan Musgrave Olby (aged 52 years) holds/has held the following directorships/partnerships in the last five years:\n\n\n\nCurrent directorships/partnerships\n\n\nPrevi...